Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer
Science Signaling · 2025
DOI: 10.1126/scisignal.adr3738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Oleksandra Aust und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitép…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Therapy-induced acquired resistance limits the clinical effectiveness of mutation-specific KRAS inhibitors in colorectal cancer (CRC). Here, we investigated whether broad-spectrum, active-state RAS inhibitors meet similar limitations. We found that KRAS-mutant CRC cell lines were sensitive to the RAS(ON) multiselective RAS inhibitor RMC-7977, given that treatment resulted in RAS-RAF-MEK-ERK pathway inhibition; halted proliferation; and, in some cases, induced apoptosis. RMC-7977 initially reduced the activity of a compartment-specific, dual-color reporter of ERK activity, with reporter reactivation emerging after long-term dose escalation. These drug-resistant cell populations exhibited distinct patterns of phospho-protein abundance, transcriptional activities, and genomic mutations, including a Y71H mutation in KRAS and an S257L mutation in RAF1. Transgenic expression of KRAS G13D, Y71H or RAF1 S257L in drug-sensitive CRC cells induced resistance to RMC-7977. CRC cells that were resistant to RMC-7977 and harboring RAF1 S257L exhibited synergistic sensitivity to concurrent inhibition of RAS and RAF. Our findings demonstrate the power of reporter-assisted screening together with single-cell analyses for dissecting the complex landscape of therapy resistance. The strategy offers opportunities to develop clinically relevant combinatorial treatments to counteract the emergence of resistant cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- Core Unit Bioinformatics (CUBI), Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- Bioportal Single Cells, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- German Cancer Consortium (DKTK) Partner Site Berlin, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
ORCID-Profile: Moritz R T Thiel, Eric Blanc, Mareen Lüthen, Viola Hollek, Rosario Astaburuaga-García, Bertram Klinger, Francisca Böhning, Alexandra Trinks, Dieter Beule, Björn Papke, David Horst, Nils Blüthgen, Christine Sers, Channing J Der, Markus Morkel
Förderung
- NCI NIH HHS
Zitieren
APA
Aust, O., Thiel, M. R. T., Blanc, E., Lüthen, M., Hollek, V., Astaburuaga-García, R., Klinger, B., Böhning, F., Trinks, A., Beule, D., Papke, B., Horst, D., Blüthgen, N., Sers, C., Der, C. J., & Morkel, M. (2025). Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer. Science Signaling. https://doi.org/10.1126/scisignal.adr3738
Vancouver
Aust O, Thiel MRT, Blanc E, Lüthen M, Hollek V, Astaburuaga-García R, et al. Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer. Science Signaling. 2025. doi:10.1126/scisignal.adr3738
BibTeX
@article{Aust2025,
author = {Aust, Oleksandra and Thiel, Moritz R T and Blanc, Eric and Lüthen, Mareen and Hollek, Viola and Astaburuaga-García, Rosario and Klinger, Bertram and Böhning, Francisca and Trinks, Alexandra and Beule, Dieter and Papke, Björn and Horst, David and Blüthgen, Nils and Sers, Christine and Der, Channing J and Morkel, Markus},
title = {Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer},
journal = {Science Signaling},
year = {2025},
doi = {10.1126/scisignal.adr3738}
}
EUVIMED